Tag Archives: BIO CEO & Investor Conference

How Industry Rates Interactions with the FDA

shutterstock_26191726

Kicking off day one of the BIO CEO & Investor Conference in New York City, panelists in the ‘How Industry Rates Interactions with the FDA’ session brought attendees good news – communication with the FDA has improved overall. “The improvements we have seen in increased communications between FDA and sponsors is based on a continuous dialogue that has been established over the past several years in which BIO has been at the forefront,” said Jonathan Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Patients Remain the Focus for the Future of Personalizing Oncology

lab_tech02

The 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City, kicked off this morning with an interactive panel of industry heavyweights discussing the growing trend to personalize oncology treatments with molecular diagnostics. Moderated by Michael King, Managing Director, Senior Research Analyst, JMP Securities. Michael helped steer the group of experts as they discussed enabling broader matching of patient-cancer-therapy, lessons learned from the Cancer Genome Atlas and the potential Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Dow Jones VentureWire: BIO Report on Venture Funding for Therapeutic Innovation

lab_tech

Today, Brian Gormley’s story – Biotech VCs Shift Away From Chronic Diseases, Report Says – highlights VC funding trends over a 10-year period. BIO released the report today showing that venture capital is shifting away from chronic diseases and increasing for rare diseases. The report categorized $38 billion of investment across more than 1,200 companies from 2004 through 2013. BIO’s report compares five-year periods before and after the financial crisis. From 2004 through 2008, for Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Announcing the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey

lab_tech

Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey. Your investment plans and budgets all include growth assumptions and market forecasts. Can you trust them? 2014 was another banner year for biotech IPOs, with 81 companies in our industry going public, an increase of nearly 90 percent over 2013. Now we turn our attention to the year ahead and what we can expect. More blue skies or dark clouds?  M&A surpassing last year Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Chairman Upton and Rep. DeGette Op-Ed: Can We Find Cures for 7,000 Diseases?

21st Century Cures Act

In a CNN.com op-ed, Energy & Commerce Committee Chairman Fred Upton (R-MI) and Representative Diana DeGette (D-CO) provide highlights of policies that they intend to propose to help get more cures and treatments for the more than 7,000 diseases for which only 500 have cures and treatments. Chairman Upton and Rep. DeGette launched the 21st Century Cures Initiative to identify areas of reform to help ‘close the gap between the science of medicine and the Read More >

Business and Investments, Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,